Notice: This company has been marked as potentially delisted and may not be actively trading. NASDAQ:LABP Landos Biopharma (LABP) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsEarningsHeadlinesInsider TradesOwnershipTrends About Landos Biopharma Stock (NASDAQ:LABP) 30 days 90 days 365 days Advanced Chart Ad Weiss RatingsTrump won. Buy this coin now.Juan Villaverde called the top and bottom of every crypto bull market since 2012. He believes Bitcoin will go to $150,000 — or more. But there’s one coin he thinks could go even higher.This could be his favorite coin. Get Landos Biopharma alerts:Sign Up Key Stats Today's Range$22.75▼$22.9450-Day Range$21.51▼$22.9352-Week Range$2.50▼$22.94Volume50,800 shsAverage Volume19,700 shsMarket Capitalization$71.77 millionP/E RatioN/ADividend YieldN/APrice Target$20.42Consensus RatingHold Company OverviewLandos Biopharma, Inc., a clinical-stage biopharmaceutical company, discovers and develops oral therapeutics for patients with autoimmune diseases. Its lead product candidate is NX-13, an oral gut-selective Nucleotide Oligomerization Domain (NLRX1), a mitochondria-associated receptor associated with the modulation of inflammatory cytokines that is in Phase 2 clinical trial to treat ulcerative colitis (UC) and completed Phase 1 to treat Crohn's disease (CD). The company's preclinical candidates in development include LABP-73, an oral and small molecule NLRX1 pathway agonist for the treatment of asthma and eosinophilic disorders; LABP-66 is an oral and small molecule NLRX1 pathway agonist for the treatment of multiple sclerosis and neurodegenerative disorders; and LABP-69, an oral PLXDC2 agonist for the treatment of rheumatoid arthritis, UC, and CD. The company has a license and collaboration agreement with LianBio Respiratory Limited to develop, manufacture, and commercialize omilancor and NX-13. Landos Biopharma, Inc. was incorporated in 2017 and is headquartered in Blacksburg, Virginia.Read More… Trump won. Buy this coin now. (Ad)Juan Villaverde called the top and bottom of every crypto bull market since 2012. He believes Bitcoin will go to $150,000 — or more. But there’s one coin he thinks could go even higher.This could be his favorite coin. Receive LABP Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Landos Biopharma and its competitors with MarketBeat's FREE daily newsletter. Email Address LABP Stock News HeadlinesGlobal Asthma Treatment Market to Cross ~USD 32 Billion by 2030 | DelveInsightOctober 9, 2024 | uk.finance.yahoo.comAbbVie Completes Acquisition of Landos BiopharmaMay 23, 2024 | prnewswire.comMan behind OpenAI makes shocking new betBillionaire Sam Altman has become one of the most powerful men in the world by running OpenAI… But there’s a far lesser known investment he’s making that could put OpenAI to shame. In fact this Sam Altman-backed company could actually become a crucial partner for OpenAI… And the US Military… not to mention hundreds of other giant companies around the globe. To make the story even crazier… this company only recently became viable, thanks to an obscure piece of legislation that President Trump signed before he left office… Which ordered the government to take this incredible new technology seriously.November 21, 2024 | DTI (Ad)LANDOS BIOPHARMA INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Landos Biopharma, Inc. - LABPMay 11, 2024 | businesswire.comLABP Stock Earnings: Landos Biopharma Misses EPS for Q1 2024May 9, 2024 | investorplace.comEx-Humira Growth Platform Drives AbbVie's Q1 Performance, Drugmaker Lifts Annual Profit OutlookApril 26, 2024 | msn.comLandos Biopharma (LABP) Price Target Increased by 154.20% to 12.96April 17, 2024 | msn.comStockholder Alert: Ademi LLP continues Investigation of the Fairness of Landos Biopharma, Inc.'s transaction with AbbVieApril 16, 2024 | prnewswire.comSee More Headlines LABP Stock Analysis - Frequently Asked Questions How were Landos Biopharma's earnings last quarter? Landos Biopharma, Inc. (NASDAQ:LABP) issued its quarterly earnings data on Friday, May, 12th. The company reported ($0.90) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($1.00) by $0.10. When did Landos Biopharma's stock split? Landos Biopharma's stock reverse split before market open on Friday, May 26th 2023. The 1-10 reverse split was announced on Friday, May 26th 2023. The number of shares owned by shareholders was adjusted after the market closes on Friday, May 26th 2023. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split. When did Landos Biopharma IPO? Landos Biopharma (LABP) raised $101 million in an initial public offering (IPO) on Thursday, February 4th 2021. The company issued 6,300,000 shares at a price of $15.00-$17.00 per share. J.P. Morgan, Jefferies and SVB Leerink acted as the underwriters for the IPO and Raymond James was co-manager. What other stocks do shareholders of Landos Biopharma own? Based on aggregate information from My MarketBeat watchlists, some other companies that Landos Biopharma investors own include NVIDIA (NVDA), Broadcom (AVGO), Meta Platforms (META), Adobe (ADBE), e.l.f. Beauty (ELF), Jabil (JBL) and Arista Networks (ANET). Company Calendar Last Earnings5/12/2023Today11/21/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:LABP CUSIPN/A CIK1785345 Weblandosbiopharma.com Phone540-218-2232FaxN/AEmployees19Year FoundedN/APrice Target and Rating Average Stock Price Target$20.42 High Stock Price Target$20.42 Low Stock Price Target$20.42 Potential Upside/Downside-10.9%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($3.99) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-21,930,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-73.00% Return on Assets-63.00% Debt Debt-to-Equity RatioN/A Current Ratio4.43 Quick Ratio4.43 Sales & Book Value Annual Sales$18 million Price / Sales3.99 Cash FlowN/A Price / Cash FlowN/A Book Value$7.41 per share Price / Book3.09Miscellaneous Outstanding Shares3,130,000Free Float3,085,000Market Cap$71.77 million OptionableNot Optionable Beta0.14 These 7 Stocks Will Be Magnificent in 2024With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.Get This Free Report This page (NASDAQ:LABP) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredThe pin that pops the AI bubbleMy new documentary explores the background to this pattern and how and why I believe it will almost certainly ...Porter & Company | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Landos Biopharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Landos Biopharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
